INSULIN PUMP THERAPY

A continuous subcutaneous insulin pump replaces the need for multiple daily injections by delivering rapid acting insulin to a patient 24 hours a day. Our most advanced insulin pump, the MiniMed™ 770G system, is automated, connected, and upgradeable so that you can focus on patient care.

MiniMed™ 770G System

The MiniMed™ 770G system features SmartGuardTM Auto Mode, which automatically adjusts insulin every 5 minutes based on the patient’s unique needs.* With Bluetooth® connectivity, the system is able to connect to a smartphone, allowing patients and their care partners to view insulin pump and continuous glucose monitoring (CGM) data remotely.

   

Explore the MiniMed™ 770G Pump System - (26:23)

See how the MiniMed™ 770G system works and how it can help your patients maintain healthy sugar levels.
More information (see more) Less information (see less)

  

need
pdf MiniMed™ 770G System Brochure (.pdf)

Learn more how the MiniMed™ 770G system automatically adjusts insulin levels and takes on more of the tasks of managing diabetes so your patients can focus more on their daily life.

2.0MB

pdf Overview of the MiniMed™ 770G Pump System Brochure (.pdf)

Learn how SmartGuard ™ Auto Mode works to keep patients' sugar levels in range and how the MiniMed™ Mobile and CareLink™ Connect apps can help you and your patients share glucose data and stay connected.

2.4MB

pdf MiniMed™ 770G System Initial Therapy Settings Reference Guide (.pdf)

View quick tips on how to start your patients on the MiniMed™ 770G system.

97KB

pdf MiniMed™ 770G System Insulin Pump Therapy for Pediatric Patients Ages 2+ Brochure (.pdf)

Learn how the MiniMed™ 770G system can help your pediatric patients achieve desired glycemic control outcomes and stay connected with their care givers.

8.2MB

*

Important Safety Information for MiniMed™ 770G System:
The MiniMed™ 770G system is for type 1 ages 2 and over. Prescription required. Individual results may vary. WARNING: Do not use SmartGuard™ Auto Mode for people who require less than 8 units or more than 250 units of insulin/day. For details, please visit http://www.medtronicdiabetes.com/support/download-library/user-guides and www.medtronicdiabetes.com/importantsafetyinformation for complete details.

MiniMed™ 630G System

The MiniMed™ 630G system has an intuitive design and several convenient features that can help your patients with type 2 and type 1 diabetes. It delivers continuous and customized doses of rapid-acting insulin 24 hours a day to match body’s needs. 

Transitioning MDI patients with Type 2 Diabetes to Insulin Pump Therapy

Dr. LaShelle Barmore, D.O. discusses the effectiveness of insulin pump therapy particularly for people with type 2 diabetes and how to transition patients from injections.



 

Minimed 630g System
pdf Automatic Background Insulin Delivery for Patients with Type 2 Diabetes - Brochure (.pdf)

Learn how the MiniMed™ 630G system can give your patients with type 2 diabetes better control and more flexibility.

801KB

pdf A Different Way to Manage Type 2 Diabetes - Study (.pdf)

Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomized open-label controlled trial.

331KB

*

Important Safety Information for MiniMed™ 630G System:
Indicated for the continuous delivery of insulin, at set and variable rates, for the management of diabetes mellitus. The MiniMed™ 630G system is approved for ages 14 and up with Guardian™ Sensor 3. The system requires a prescription. WARNING: Do not use the Suspend on low feature to prevent or treat low blood glucose. For details, please visit http://www.medtronicdiabetes.com/support/download-library/user-guides and www.medtronicdiabetes.com/importantsafetyinformation for complete details.

CONTACT

Would you like to learn more about Medtronic products?

Contact us

Sensor-Augmented Pump Outcomes

pdf Education Brief: Medtronic Pediatric Hybrid Closed Loop Pivotal Trial in Patients 2-6 Years Old (.pdf)

The following education brief provides a summary Medtronic Pediatric Hybrid Closed Loop Pivotal Trial in patients 2-6 years old results.

157KB